Johnson & Johnson Sees $1.78M Bullish Call Sweep as Stock Trades Near 52-Week Highs

By TrendSpider Editor

A single unusual options contract totaling $1,777,230 in premium hit the tape for Johnson & Johnson on Wednesday, with a trader placing a sizeable call position suggesting expectations for further upside ahead of the June expiration. JNJ shares are currently trading at $223.67, down 0.85% on the ses

Johnson & Johnson Sees $1.78M Bullish Call Sweep as Stock Trades Near 52-Week Highs

A single unusual options contract totaling $1,777,230 in premium hit the tape for Johnson & Johnson on Wednesday, with a trader placing a sizeable call position suggesting expectations for further upside ahead of the June expiration. JNJ shares are currently trading at $223.67, down 0.85% on the session, but remain well within the upper half of their 52-week range of $146.115 to $251.705. The positioning of this call contract above current market price points to a measured but meaningful bet that JNJ has room left to run.

Key Drivers of the JNJ Stock Move

• Main Catalyst: One unusual call contract was flagged today targeting the $230 strike with a June 18, 2026 expiration. The contract carried $1,777,230 in total premium and printed with an open interest utilization of 37%, indicating meaningful but not exhaustive existing positioning at this level.
• Bull Case: The $230 strike sits roughly 2.8% above the current price of $223.67, making it an out-of-the-money bet that does not require an enormous move to become relevant. With JNJ having already traded as high as $251.705 over the past 52 weeks, the $230 target represents a level the stock has previously cleared with room to spare, lending credibility to the thesis.
• Bear Case: The contract is currently out of the money, and with JNJ slipping 0.85% today, near-term momentum is not confirming the bullish options thesis. If the stock fails to reclaim $230 before the June 18 expiration, the full $1,777,230 in premium is at risk. The 37% open interest reading also suggests this strike has seen prior activity, meaning today's flow does not represent entirely fresh conviction.

The forward setup for JNJ carries both opportunity and headline risk heading into the back half of May and into June. The June 18 expiration window coincides with a period in which large-cap healthcare names are often sensitive to legislative developments around drug pricing, Medicare negotiation updates, and any litigation newsflow. Johnson & Johnson has faced ongoing scrutiny related to its talc litigation settlements, and any incremental developments on that front could weigh on or support sentiment heading into options expiry. For the $230 call to pay off, bulls will need to see the broader market cooperate and JNJ-specific catalysts hold firm over the next six weeks.

JNJ Unusual Options Activity

One unusual contract was flagged in Wednesday's session for Johnson & Johnson, representing the entirety of the $1,777,230 in total options premium detected:

• Type: Call | Strike: $230 | Expiry: June 18, 2026 | Volume (Size): 4,557 contracts | Open Interest Utilization: 37% | Moneyness: Out of the Money

The size of 4,557 contracts at the $230 strike with a June 18 expiration stands out as the sole unusual contract flagged today. The out-of-the-money positioning and the concentrated single-contract structure give this flow a directional character rather than a hedging profile, suggesting a trader is making an outright bullish bet on JNJ over the next approximately six weeks.

JNJ Seasonality

Historically, large-cap healthcare names like JNJ have shown a tendency toward relative stability in the May through June window as defensive rotation picks up mid-year. A June 18 expiration aligns closely with the mid-year period when healthcare stocks have at times benefited from portfolio rebalancing flows away from more cyclically sensitive sectors.

JNJ Relative Performance

JNJ's current price of $223.67 places it comfortably above the midpoint of its 52-week range of $146.115 to $251.705, reflecting sustained strength relative to where the stock traded at its yearly low. The modest 0.85% decline on Wednesday is consistent with broad market caution rather than any JNJ-specific deterioration, and the stock remains in a strong long-term position within the large-cap healthcare peer group heading into the June options expiration window.